ARRY-502

ARRY-502 is an orally active, potent and selective CRTh2 antagonist. ARRY-502 blocks PGD2-mediated Th2 inflammation (e.g., eosinophil activation, airway hyperresponsiveness) . ARRY-502 is promising for research of Th2-related asthma[1].

Product Specifications

CAS Number

[1202891-16-4]

UNSPSC

12352005

Target

Prostaglandin Receptor

Related Pathways

GPCR/G Protein

Field of Research

Inflammation/Immunology

Smiles

OC([C@@H]1C2=CC(Cl)=C(OC3=CC=C(C=C3)C(NCCC4=C(C=C(C=C4)Cl)OC)=O)C=C2OCC1)=O

Molecular Formula

C26H23Cl2NO6

Molecular Weight

516.37

References & Citations

[1]Wenzel S E, et al. Safety and efficacy of ARRY-502, a potent, selective, Oral CRTh2 antagonist, in patients with mild to moderate Th2-driven asthma[J]. Journal of Allergy and Clinical Immunology, 2014, 133 (2) : AB4.